Journal
PATHOLOGY & ONCOLOGY RESEARCH
Volume 26, Issue 3, Pages 1451-1458Publisher
SPRINGER
DOI: 10.1007/s12253-019-00710-4
Keywords
Immunotherapy; PD-L1; LGALS1; Galectin1; Clear cell renal carcinoma; Immune checkpoint
Funding
- National Natural Science Foundation of China [81500544, 81873605, 81700379, 81500561] Funding Source: Medline
- the Research on The Basis and Frontier of Chongqing [cstc2016jcyjA0049] Funding Source: Medline
Ask authors/readers for more resources
Immunotherapy base on immune checkpoint inhibitor had obtained significant progress in extending the survival of clear cell renal carcinoma (ccRCC) patients. In order to further improve the efficiency of immunotherapy, novel immune checkpoint inhibitors needed to be developed. Differentially expressed genes (DEGs) between healthy kidney tissues and ccRCC tissues had been found from GSE68417 by GEO2R online analysis tool. Correlation analysis and Kaplan-Meier survival analyses were based on UALCAN database. Analyses of the outcome of anti-PD1 treatment had been found from GSE67501 dataset. At first, 9 genes with higher expression were associated with shorter overall survival time. More importantly, higher expression of LGALS1 was correlated with a profitable outcome of anti-PD1 treatment and the combined the expression level of PD-L1 and LGALS1 together could more efficiently predict the outcome of anti-PD1 treatment than using PD-L1 alone. At last, the genes which correlated with LGALS1 expression in ccRCC patients were enriched in TNF alpha Signaling Pathway which is mainly correlated with T cell apoptosis and survival. Together, these suggest LGALS1 could be a potential immune checkpoint, which could promote tumor progression through affecting T cell survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available